• 1
    Dakhale G, Khanzode S, Khanzode S et al. Oxidative damage and schizophrenia: The potential benefit by atypical antipsychotics. Neuropsychobiology 2004; 49: 205209.
  • 2
    Fendri C, Mechri A, Khiari G et al. Oxidative stress involvement in schizophrenia pathophysiology: A review. Encephale 2006; 32: 244252.
  • 3
    Gama CS, Salvador M, Andreazza AC et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: A study of patients treated with haloperidol or clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 512515.
  • 4
    Hernandez MV, Ramos-Loyo J, Luquin S et al. Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenia. J. Psychiatr. Res. 2007; 41: 652658.
  • 5
    Li HC, Chen QZ, Ma Y et al. Imbalanced free radicals and antioxidant defence systems in schizophrenia: A comparative study. J. Zhejiang Univ. Sci. B. 2006; 7: 981986.
  • 6
    Mahadik SP, Mukherjee S. Free radical pathology and the antioxidant defense in schizophrenia. Schizophr. Res. 1996; 19: 117.
  • 7
    Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr. Res. 2003; 62: 205212.
  • 8
    Ustundag B, Atmaca M, Kirtas O et al. Total antioxidant response in patients with schizophrenia. Psychiatry Clin. Neurosci. 2006; 60: 458464.
  • 9
    Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: An overview of the evidence and its therapeutic implications. CNS Drugs 2001; 15: 287310.
  • 10
    Akyol O, Herken H, Uz E et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002; 26: 9951005.
  • 11
    Reddy R, Sahebarao MP, Mukherjee S et al. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol. Psychiatry 1991; 30: 409412.
  • 12
    Yao JK, Reddy R, McElhinny LG et al. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr. Res. 1998; 32: 18.
  • 13
    Zhang XY, Zhou DF, Cao LY et al. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: Association with dyskinetic movements. Schizophr. Res. 2003; 62: 245250.
  • 14
    Sarandol A, Kirli S, Akkaya C et al. Oxidative-antioxidative systems and their relation with serum S 100 B levels in patients with schizophrenia: Effects of short term antipsychotic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 11641169.
  • 15
    Mahadik SP, Shendarkar NS, Scheffer RE et al. Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls. Prostaglandins Leukot. Essent. Fatty Acids 1996; 55: 6570.
  • 16
    Peet M, Laugharne J, Rangarajan N et al. Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment. Int. J. Clin. Psychopharmacol. 1993; 8: 151153.
  • 17
    Zhang XY, Zhou DF, Su JM et al. The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J. Clin. Psychopharmacol. 2001; 21: 8588.
  • 18
    Zhang XY, Zhou DF, Zhang PY et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 2001; 62: 878879.
  • 19
    Peet M, Horrobin DF, E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 2002; 36: 718.
  • 20
    Arvindakshan M, Ghate M, Ranjekar PK et al. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr. Res. 2003; 62: 195204.
  • 21
    Skosnika PD, Yao JK. From membrane phospholipid defects to altered neurotransmission: Is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot. Essent. Fatty Acids 2003; 69: 367384.
  • 22
    Tsai G, Goff DC, Chang RW et al. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry 1998; 155: 12071213.
  • 23
    Yao JK, Reddy R, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. J. Psychiatr. Res. 2000; 97: 137151.
  • 24
    Khan MM, Evans DR, Gunna V et al. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002; 58: 110.
  • 25
    Zhang XY, Zhou DF, Cao LY et al. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: Association with positive symptoms. J. Psychiatr. Res. 2003; 117: 8588.
  • 26
    Kunz M, Gama CS, Andreazza AC et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substance in different phase of bipolar disorder and in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008; 32: 16771681.
  • 27
    Herken H, Uz E, Ozyurt H et al. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol. Psychiatry 2001; 6: 6673.
  • 28
    Zhang XY, Tan YL, Cao LY et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006; 81: 291300.
  • 29
    Gama CS, Salvador M, Andreazza AC et al. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci. Lett. 2008; 433: 270273.
  • 30
    Yao JK, Reddy R, McElhinny LG et al. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J. Psychiatr. Res. 1998; 32: 385391.
  • 31
    Al-chalabi BM, Thanoon AJ, Ammed FA. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology 2009; 59: 811.
  • 32
    American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. DSM-IV. American Psychiatric Association Press, Washington, DC, 1994.
  • 33
    Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin. Biochem. 2004; 37: 112119.
  • 34
    Erel O. A new automated colorimetric method for measuring total oxidant status. Clin. Biochem. 2005; 38: 11031111.
  • 35
    Kosecik M, Erel O, Sevinc E et al. Increased oxidative stress in children exposed to passive smoking. Int. J. Cardiol. 2005; 100: 6164.
  • 36
    Lukoff D, Nuechterlein KH, Ventura J. Appendix A: manual for the expanded brief psychiatric rating scale (BPRS). Symptom monitoring in the rehabilitation of schizophrenic patients. Schizophr. Bull. 1986; 12: 594602.
  • 37
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261276.
  • 38
    Kostakoglu S, Tiryaki BA. The validity and reliability of the Turkish version of the Positive and Negative Syndrome Scale (PANSS). Turk. J. Psychol. 1999; 14: 2332.
  • 39
    Ranjekar PK, Hinge A, Hegde MV et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. J. Psychiatr. Res. 2003; 121: 109122.
  • 40
    Pae UC, Paik IH, Lee C et al. Decreased plasma antioxidants in schizophrenia. Neuropsychobiology 2004; 50: 5456.
  • 41
    Kuloglu M, Ustundag B, Atmaca M et al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem. Funct. 2002; 20: 171175.
  • 42
    Evans DR, Parikh VV, Khan MM et al. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot. Essent. Fatty Acids 2003; 69: 393399.
  • 43
    Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. J. Psychiatr. Res. 1998; 80: 2939.
  • 44
    Reddy RD, Yao JK. Free radical pathology in schizophrenia: A review. Prostaglandins Leukot. Essent. Fatty Acids 1996; 55: 3343.
  • 45
    Berk M, Copolov D, Dean O et al. N-Acetyl cysteine as a glutathione precursor for schizophrenia: A double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 2008; 64: 361368.
  • 46
    Matsuzawa D, Obata T, Shirayama Y et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: A 3T 1H-MRS study. PloS ONE 2008; 3: e1944.
  • 47
    Mukherjee S, Mahadik SP, Scheffer R et al. Impaired antioxidant defense at the onset of psychosis. Schizophr. Res. 1996; 19: 1926.